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Abstract
Meningiomas account for approximately 30% of all primary central nervous system tumors
and are found in half of neuroﬁbromatosis type 2 patients often causing signiﬁcant morbid-
ity. Although most meningiomas are benign, 10% are classiﬁed as atypical or anaplastic,
displaying aggressive clinical behavior. Biallelic inactivation of the neuroﬁbromatosis 2
(NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and
60%ofsporadicmeningiomas.Deletionofthep16INK4a/p14ARFlocusisfoundinbothbenign
and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncom-
mon. Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenovi-
ral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma
formation. Here, we report that additional nullizygosity for p16Ink4a increases the frequency
of meningioma and meningothelial proliferation in these mice without modifying the tumor
grade. In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of
mutant mice, we were able to detect meningothelial proliferation and meningioma develop-
ment opening the way to future studies in which therapeutic interventions can be tested as
preclinical assessment of their potential clinical application.
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INTRODUCTION
Meningiomas account for approximately one-fourth of all primary
central nervous system tumors. They usually affect older adults,
particularly women, and are often associated with signiﬁcant mor-
bidity (13).Although most meningiomas are benign,World Health
Organization (WHO) grade I lesions, 10% of meningiomas are
classiﬁed as atypical (WHO grade II) or anaplastic (WHO grade
III) (10), displaying aggressive clinical behavior and leading to
increased patient morbidity and mortality (27). One of the genetic
mechanisms underlying meningioma tumorigenesis includes early
inactivation of the neuroﬁbromatosis 2 (NF2) tumor suppressor
gene (12, 18). Previously, we inactivated Nf2 in homozygous con-
ditional knockout mice by adenoviral Cre (adCre) delivery into
arachnoid cells through the cerebrospinal ﬂuid (CSF) of newborn
mice (6). We have shown that biallelic loss of Nf2 is rate-limiting
for meningioma development with mice developing a range of
meningioma subtypes histologically similar to WHO grade I
human meningiomas.
In humans, higher-grade meningiomas are aggressive and are
associatedwithpoorclinicaloutcomeandwithfrequentrecurrence
after surgery and radiotherapy. So far, only few of the individual
genes affected by the chromosomal aberrations found in atypical
and malignant meningiomas are known. Deletion of the p16INK4a/
p14ARF locus or monosomy of chromosome 9 was found in 17% of
grade I, 52% of grade II, and 74% of grade III meningiomas (15)
resulting in loss of p16 expression (23). The majority of grade
III meningiomas either show homozygous deletions of
p16INK4a,p14ARF, and CDKN2B, mutations in p16INK4a and p14ARF,
or lack of expression of one or more of these genes (3). The
p16INK4a/p14ARF locus encodes two distinct cell cycle inhibitory
proteins, p16INK4a and p14ARF (p19Arf in the mouse) by alternative
ﬁrst-exon usage and alternative reading frames (20). p16INK4a
arrests cells in the G1 phase of the cell cycle by binding the cyclin-
dependant kinases CDK4 and CDK6 and inhibiting their ability to
phosphorylate and inactivate the retinoblastoma (RB1) family of
tumor suppressor proteins (22). p14ARF acts through MDM2 to
stabilize and activate the key checkpoint protein p53, which can
arrest cells in both G1 and G2 or induce apoptosis (20). In the
present study, we evaluated the effects in meningioma initiation
and progression of p16Ink4a loss with retention of p19Arf in synergy
with Nf2 loss.
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tumor initiation and progression, genetically modiﬁed (GEM)
cancer models can be used as “ﬁlters” for the screening and selec-
tion of therapeutic agents for human trials (5), and are particularly
valuable for rare tumors types, such as brain tumors (2). However,
evaluatingtherapeuticagentsinapertinentmousemodelofmenin-
gioma is challenging because of low tumor penetrance and to their
relatively slow growth rate.Thus, small animal imaging is required
to monitor tumor growth and response to therapeutic modalities.
As in humans meningiomas are routinely detected and followed
by magnetic resonance imaging (MRI), we sought to determine
whether small animal MRI could detect abnormal meningeal pro-
liferations in the living mouse.As an initial step toward using these
mice as a preclinical model of meningioma, we have deﬁned an
imaging protocol based on gadolinium enhancement to delineate
tissuemorphologyandpathology,asusedforhumanmeningiomas.
METHODS
Mice
To obtain Nf2ﬂox2/ﬂox2;p16Ink4a*/* mice, Nf2ﬂox2/ﬂox2 mice (4) on the
FVB/N background were bred to p16Ink4a*/* mice (11) on a FVB/N/
129Ola mixed background, and the resulting Nf2ﬂox2/+; p16Ink4a*/+
mice were intercrossed. All mice used for this analysis were pre-
dominantlyFVB/Nmixedstrainwithcontemporaneouslittermates
serving as controls. Pathogens were tested on a quarterly basis, and
all serologies tested were negative throughout the study.All animal
care and experimentation reported herein were conducted in com-
pliance with the guidelines and with the speciﬁc approval of Insti-
tutional Animal Care and Use Committee of the French Depart-
ment ofAgriculture.
Injection of adenoviruses
Cre recombinase was targeted to the mouse leptomeninges by
direct injection of 3 mL( 1¥ 108 plaque-forming units) of adCre
suspension into the subarachnoidal space on postnatal day 2 by
trans-orbital or subdural approach, as previously described (6).
Histopathology and immunohistochemistry
Mice were sacriﬁced by CO2 inhalation when seriously ill (rarely)
or after the last magnetic resonance (MR) image acquisition at 15
months and a necropsy was performed. Histopathological analysis
was performed as previously described (6).
PGDSimmunohistochemistrywascarriedoutonadjacentparaf-
ﬁn sections using afﬁnity-puriﬁed rabbit polyclonal antibodies
(1:500; Santa Cruz, CA, USA sc-14825) and standard techniques
(DakoCytomation, Glostrup, Denmark).The terminology used for
the description of the meningothelial lesions in the mouse models
relies on the WHO classiﬁcation of human tumors as a reference
(13). The term “meningothelial hyperplasia” is not used, as in
humans that refers to the proliferation of reactive, normal arach-
noid cells. “Meningothelial proliferation” refers to very small
(microscopic) lesions composed of meningothelial cells that repre-
sentearlytumorformation.“Meningioma”referstoalargerlesion,
with features similar to a WHO grade I meningioma in human.
“Meningioma en plaque” refers to a meningioma with a growth
pattern of diffuse thickening of the dura, similar to meningioma en
plaque in humans.
Electron microscopy
Parafﬁn-embeddedtissuewascutintoninepieces,placedinxylene
overnight, rehydrated in graded ethanols (100% to 25%), and then
placed in gluteraldehyde. Subsequently, the tissue was post-ﬁxed
in osmium tetroxide, stained with uranyl acetate, dehydrated in
graded ethanol solutions, inﬁltrated with propylene oxide/Epon
mixtures, ﬂat embedded in pure Epon, and polymerized overnight
at 60°C. One-micrometer sections were cut, stained with toluidine
blue, and examined by light microscopy. The best section contain-
ing meningioma was chosen to proceed for electron microscopy
study and trimmed accordingly. Thin sections were cut with an
LKB8801 ultramicrotome and diamond knife, stained with Sato’s
lead, and examined in a Phillips 301 transmission electron
microscope.
MRI
MRIwasusedtoidentifyandlocalizemeningiomas.MRstudywas
performed on a 4.7 Tesla microimaging system (Biospec, Bruker
BioSpin MRI, Inc., Ertlingen, Germany). The system consists of
three-axis self-shielded magnetic ﬁeld gradients, with 30 G/cm
maximum gradient amplitude in all three channels. Under anesthe-
sia by inhalation of 1%–2% of isoﬂurane (IsoFlo®,Abbott Labora-
tories, Abbot Park, IL, USA), all animals were intraperitoneally
injected (1) a MR contrast agent, Gd-DTPA (Magnevist®, Scher-
ing,Leverkusen,Germany)atadoseof0.8 mL/kgbodyweightand
placed 15 minutes later in the radio frequency coil (inside diameter
35 mm). First the localizer imaging with a ﬁrst echo sequence
(rapid acquisition with relaxation enhancement: RARE) was
conducted on three orthogonal axes. Subsequently, transverse
T2-weighted images (T2-WIs) and T1-weighted images (T1-WIs)
were acquired with a RARE and a conventional spin-echo
sequence, respectively, on entire brain.A pulse repetition time and
echo time were 2000 and 40 ms for T2-WI and 500 and 11 ms for
T1-WI. Other parameters were: 3 cm ﬁeld of view, 128 ¥ 128
matrix size, eight (for T2-WI) and four (for T1-WI) averages,
resulting in a total scan time of approximately 2.4 and 4.5 minutes,
respectively.Somerelevantmicewerereimagedbeforeinjectionof
contrast agent to get T1-weighted images without contrast
enhancement. After the brain imaging, some animals that showed
neurological symptoms were repositioned and subjected to spinal
cord imaging. After the localization, spinal cords were imaged in
1 mm sagittal sections. The other imaging parameters were the
same as those in the brain imaging described above. The MRI
ﬁndings were qualitatively analyzed by two experienced investiga-
tors, M.K. and M.T., with consensus. MR studies were repeated at
6,9,12,and15monthsfollowedbypathologicalexaminationofall
mice.
Statistics
Signiﬁcant differences in survival and tumor development were
identiﬁed using c2 test; P < 0.05 was considered signiﬁcant.
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Additional nullizygosity for p16
Ink4a increases
the rate of meningioma development
and meningothelial proliferation in
adCre;Nf2
ﬂox2/ﬂox2 mice
To investigate the potential synergy of Nf2 inactivation and
homozygous p16Ink4a mutation in meningioma development, a
cohort of 32 Nf2ﬂox2/ﬂox2;Ink4a*/* mice were injected with adCre
and compared with 80 adCre-injected Nf2ﬂox2/ﬂox2. As control
groups, 10 adLacZ-injected Nf2ﬂox2/ﬂox2 mice and eight adCre-
injected FVB/N WT mice were used. The survival of
adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* mice was not reduced compared
with that of adCre;Nf2ﬂox2/ﬂox2, but the rate of meningioma devel-
opment was signiﬁcantly higher in adCre;Nf2ﬂox2/ﬂox2;Ink4a*/*
(10 of 27 histologically examined mice; 37%) compared with
adCre;Nf2ﬂox2/ﬂox2 (9 of 72 histologically examined mice; 13%)
mice (c2, P < 0.01). The other phenotypic abnormalities are listed
in Table 1. Histologically, all the meningiomas had features of
benign neoplasms (WHO grade I) similar to benign human menin-
giomas of meningothelial, transitional, psammomatous, or ﬁbro-
blastic histological subtypes. Two patterns of growth were
identiﬁed in mouse meningiomas: a diffuse thickening menin-
gioma en plaque-like pattern (Figure 1A), and a discrete nodular
pattern (Figure 1B). In two of 10 meningiomas found in
adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* mice, features that in human tumors
may be called “atypical” (one feature in each tumor) were
observed: prominent nucleoli (Figure 1C) and crowding of the
cells, but neither had enough atypical features to be called atypical
meningioma by the currentWHO classiﬁcation of human tumors.
Diagnostic ultrastructural features of meningioma, including
interdigitating cell processes and desmosomal intercellular junc-
tions, were found in one adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* mouse menin-
gioma analyzed by electron microscopy (Figure 1D,E). Human
arachnoid cells speciﬁcally express Prostaglandin D2 synthase
(PGDS) and intense PGDS immunopositivity is observed in about
100% of human meningothelial and 50% of ﬁbroblastic meningio-
mas (8, 29). We found the PGDS staining pattern of normal arach-
noid in mice is similar to that observed and reported in humans
(data not shown).The immunostaining for PGDS in normal arach-
noidcells,inbothhumanandmouse,showsintracytoplasmicgran-
ules in perinuclear distribution. Almost all mouse meningiomas
showed some positive staining. In some cases strong staining was
seen within some regions of the tumor (patchy distribution)
(Figure 1F), and in other tumors, only few scattered positive or
weakly positive cells were present in the tumor (Figure 1G). Inter-
estingly, in most cases PGDS staining of tumor cells (Figure 1H)
was different from that seen in the adjacent normal arachnoid cells
(Figure 2A,C) and in meningothelial proliferation (Figure 2B,D):
with fewer, ﬁne granules dispersed in the cytoplasm the pattern of
diffuse cytoplasmic staining (rarely perinuclear). In some cases, at
the injection site there was a diffuse thickening of the arachnoid,
which may represent either a diffuse meningioma en plaque or
meningothelial proliferation (early tumor), an lesion that we previ-
ouslyassociatedwithmouseleptomeningealtumorigenesis(6).We
excluded a reactive process from the differential diagnosis of these
subdural thickenings as these patterns were never observed in the
control cohorts of adLacZ-injected Nf2ﬂox2/ﬂox2 mice and adCre-
injected FVB/NWT mice.
Meningothelial proliferation was observed more frequently in
adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* (21/27; 77%) than in adCre;Nf2ﬂox2/ﬂox2
(33/72; 46%) mice (c2, P < 0.01). Consequently, hydrocephalus
caused by meningothelial proliferation impeding CSF ﬂow was
more frequent in adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* mice (Table 1).
Other phenotypic abnormalities observed included osteomas at
the adCre injection site, presumably induced by biallelic Nf2 inac-
tivation in a neural crest precursor (4, 6, 17), and liver tumors
(6). The rate of osteomas and liver tumors (three hepatocel-
lular and two cholangio-carcinomas) development was higher in
adCre;Nf2ﬂox2/ﬂox2;Ink4a*/* mice (Table 1).
Altogether, these data indicate that in the mouse homozygous
inactivation of p16ink4 tumor suppressor gene, with retained p19Arf
function,synergizeswithNf2lossinmeningiomainitiation,butnot
in meningioma progression.
Development of a preclinical model for
NF2-related meningiomas: murine meningiomas
show radiological features of
human meningiomas
Because meningiomas are routinely detected and followed by
MRI in patients, we sought to determine whether small animal
MRI could detect leptomeningeal pathology (meningothelial
Table 1. Summary of the phenotypic
consequences of transorbital (t.o.) or subdural
(s.d.) adCre injection in Nf2
ﬂox2/ﬂox2 and
Nf2
ﬂox2/ﬂox2;Ink4a*/* mice.
Phenotypic abnormality adCre;Nf2
ﬂox2/ﬂox2
(%)
adCre;Nf2
ﬂox2/ﬂox2;
Ink4a*/* (%)
t.o.
(n = 40)
s.d.
(n = 32)
t.o.
(n = 13)
s.d.
(n = 14)
Meningioma 6 (15) 3 (10) 5 (38)* 5 (36)*
Intracranial 6 (15) 3 (10) 5 (38) 2 (14)
Spinal 0 0 0 3 (21)
Meningothelial proliferation 19 (48) 14 (44) 11 (85)* 10 (71)*
Osteoma 22 (55) 19 (59) 9 (69) 12 (86)*
Osseous metaplasia (trigeminal nerve) 1 (2) 0 2 (15) 0
Liver tumor 3 (7) 2 (6) 2 (15)** 3 (21)**
Hydrocephalus 17 (43) 9 (28) 9 (69)** 6 (43)**
*c
2, P < 0.01; **c
2, P < 0.05.
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meningiomas. A. Hematoxilin and eosin-stained
section showing a transitional meningioma en
plaque overlying the brainstem. B,C. Transitional
meningioma covering the right trigeminal nerve.
Some cells have prominent nucleoli, reminiscent
of atypical features in human tumors (arrows). D.
Ultrastructural study of a large transitional spinal
meningioma, using parafﬁn-embedded material,
demonstrated features characteristic of human
meningioma. The arrow indicates tight junctions
and asterisks show complex interdigitating cell
processes. E. Detail (higher magniﬁcation) of the
image in D. Immunostaining for Prostaglandin D2
synthase (PGDS) in murine meningiomas. Mouse
meningiomas show two different PGDS staining
patterns. F. Transitional meningioma showing
multifocal process with both meningioma en
plaque and discrete nodules. The “en plaque” part
of the tumor shows multiple layers with strong
cytoplasmic staining. G. Fibroblastic meningioma
with regional positivity for PGDS. In some areas,
the cytoplasmic staining is dispersed with few,
abnormally distributed granules. H. Higher
magniﬁcation reveals PGDS immunoreactive
granules dispersed in the cytoplasm.
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the histological ﬁndings with the radiological appearance of men-
ingothelial proliferations and meningiomas, we analyzed 27
adCre;Nf2ﬂox2/ﬂox2;Ink4a*/*, 72 adCre;Nf2ﬂox2/ﬂox2 and 9 adLacZ-
injected Nf2ﬂox2/ﬂox2 mice (as negative control) by serial MRI
follow-up (6, 9, 12 and 15 months). At the end of the MRI
follow-up period, all mice were sacriﬁced and processed for histo-
logicalanalysis.Todetermineifmousemeningiomasenhancewith
gadolinium-based magnetic resonance contrast agent (Gd-DTPA),
as typically observed in human meningiomas, Gd-DTPA was
injected intraperitoneally before MRI. Pathological gadolinium
enhancement was observed in 75% of the intracranial mouse men-
ingiomas (Figures 3 and 4). Isolated meningiomas (ie, without
meningothelial proliferation, n = 8) showed strong gadolinium
enhancement appearing as thick, linear, or rounded shapes
(Figures 3B and 4A,B). These radiological features are similar to
those of human meningiomas showing iso or hyposignal on
T1-weighted sequences and strong and homogenous contrast
Figure 2. Pathological characterization of
meningothelial proliferation in mice.
Hematoxilin and eosin-stained sections
showing (A) a normal arachnoid monolayer (a)
and dura mater (d) and (B) meningothelial
proliferation (a*) characterized by multiple
layers of arachnoid cells. (C) Immunostaining
for Prostaglandin D2 synthase (PGDS) of
mouse normal leptomeninges and (D)
meningothelial proliferation. Similar PGDS
staining patterns of normal arachnoid and
meningothelial proliferation showing
intracytoplasmic granules with perinuclear
distribution.
Figure 3. Murine intracranial meningiomas
show common magnetic resonance imaging
(MRI) features of human meningiomas. A
right-side transorbital-injected adCre;Nf2
ﬂox2/ﬂox2
mouse was followed by serial MRI. A. Coronal
T1-weighted image after Gd-DTPA injection at
12 months showing normal structures with
moderate gadolinium enhancement of
trigeminal nerves (arrowheads). B. Coronal
T1-weighted image after Gd-DTPA injection at
15 months showing intense homogeneous
Gd-DTPA enhancement above right trigeminal
nerve (arrowhead) corresponding to a
histologically conﬁrmed right supratrigeminal
transitional meningioma. (C) Coronal
T1-weighted image and (D) T2-weighted image
of the meningioma in B showing typical MRI
features of human meningiomas:
homogeneous isointensity with cerebral cortex
on non-enhanced T1-weighted and
T2-weighted sequences (arrowhead).
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hyperintensity on T2-weighted MRI, was observed. Some menin-
giomas en plaque were found nested within areas of meningoth-
elial proliferation (n = 4), with images of linear gadolinium
enhancement(Figure 4C).Meningothelialproliferationwasidenti-
ﬁed in 70% of the cases by linear gadolinium enhancement and/or
hydrocephalus. Hydrocephalus was always easily detected on T1-
and on T2-weighted sequences (Figure 4A). Altogether, MRI
allowed the diagnosis of meningothelial proliferation with a sensi-
tivity of 70% and a speciﬁcity of 78% (Table 2).
Radiological features of meningothelial proliferation (linear
gadolinium enhancement and/or hydrocephalus) were present as
early as 6 months and did not evolve over time. In contrast, an
increasing incidence of meningiomas was observed at later time
points: 9, 12, or 15 months (Figure 3A,B). Some histologically
conﬁrmed meningiomas were not identiﬁed by MRI (4/16; 25%).
They corresponded to very small tumors in two cases and to com-
pletely calciﬁed meningiomas in two other cases where, as
expected based on experience in human pathology, no contrast
enhancement was seen onT1-weighted sequences.
In contrast, three false-positive cases corresponded to volumi-
nousosseousmetaplasiadevelopingwithinthetrigeminalganglion
ipsilateral to the transorbital injection site. Osseous metaplasia is
presumably induced by biallelic Nf2 inactivation in neural crest
precursor cells as observed in conditional (P0) Nf2 knockout mice
(4). Thus, radiological criteria can be drawn allowing differential
diagnosis of osseous metaplasia of the trigeminal ganglion vs.
suprasellar meningioma: strong gadolinium enhancement of the
enlarged trigeminal nerve vs. gadolinium enhancement overlying
normal-sized trigeminal nerve (Figure 3D). As in our previous
series, because of adCre diffusion through the CSF circulation,
spinal meningiomas (n = 3) were found in adCre;Nf2ﬂox2/ﬂox2;
Figure 4. Some examples of coronal
Gd-DTPA-enhanced T1-weighted magnetic
resonance (MR ) images after transorbital
(A,B,D) or subdural (C) adCre injection. A.
Arrowhead indicates lateral round Gd-DTPA
enhancement corresponding to a ﬁbroblastic
meningioma associated with hydrocephalus
characterized by enlarged ventricles
(asterisks). B. Arrowhead indicates abnormal,
thick Gd-DTPA enhancement corresponding to
a histologically conﬁrmed meningothelial
meningioma that would be deﬁned as olfactory
meningioma in human pathology. A
hypointense signal corresponding to an
osteoma is indicated by an asterisk. C.
Meningioma en plaque nested within areas of
meningothelial proliferation revealed by lateral
linear thick Gd-DTPA enhancement
(arrowhead). D. Imaging of a false-positive
case of meningioma. Coronal T1-weighted
image after Gd-DTPA injection showing
moderate gadolinium enhancement of
enlarged trigeminal nerves (arrowhead).
Histological analysis revealed osseous
metaplasia developing within the trigeminal
nerve ipsilateral to the transorbital injection
site.
Table 2. Correlation of pathological ﬁndings of
meningioma and meningothelial proliferation
with intracranial magnetic resonance imaging
(MRI) appearance.
MRI result Pathological ﬁnding
Meningioma
n = 16
Meningothelial
proliferation
n = 54
No meningothelial
proliferation
n = 45
“Positive” gadolinium enhancement 8* 8† 3
Gadolinium enhancement and
hydrocephalus
41 1 0
Hydrocephalus 0 19 7
Total 12 38 10
“Negative” 4 16 35
*Linear or rounded gadolinium enhancement.
†Linear gadolinium enhancement.
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ing with paraparesis, a neurological signs suggestive of spinal cord
compression (Figure 5A,C). Radiologically, these tumors, appear-
ing as a dural-based mass with a dural tail (Figure 5B), presented
the typical features of human spinal meningiomas compressing
the spinal cord and enhancing brightly and homogenously with
contrast.
DISCUSSION
Deletion of the INK4a-ARF locus is one of the most frequent
genomic alterations found in human high-grade meningiomas (15)
encouraging the question of which protein provides the relevant
tumor suppressor activity of the locus. Here we have shown that
Ink4a nullizygosity enhances the incidence of meningioma forma-
tion induced by somatic Nf2 loss in arachnoid cells, and that in
mice p16ink4a loss is not a critical event associated with malignant
progression of meningioma.
The role of Ink4a-Arf in tumor suppression in mice has been
extensively studied (21). Mice deﬁcient for both p16Ink4a and p19Arf
developed a variety of spontaneous tumors within their ﬁrst year of
life (19).This phenotype could to a large extent be attributed to the
lossofArfaloneastheArfnullmiceshowedmostofthesametraits
as the Ink4a-Arf null mice (7) and Ink4a*/* mice showed only a
subtle predisposition to spontaneous tumor formation later in life
(>15 months) (11). In this study we did not observe tumors related
to p16Ink4a loss as the end point was set at 15 months of age. It has
been shown previously that NF2 expression induces a decrease in
cyclin D1 and CDK4 kinase activity, concomitant with dephospho-
rylation of pRB and reduced DNA synthesis (9, 28). Thus, the
synergy we observed between Nf2 and p16Ink4 mutations in menin-
gioma development reﬂects the concomitant loss of two regulators
of CDK4 activity resulting in cyclin D1 activation. Remarkably,
meningiomas developed in double-mutant mice do not show fea-
tures characteristic of high-grade meningioma suggesting that loss
of the p14Arf rather than the p16Ink4a component of the locus is
critical for malignant transformation of meningiomas. We have
previously conﬁrmed that in mice (6), as in humans (3) p53 inacti-
vation does not synergize with Nf2 loss in meningioma initiation
and progression.Thus, the suppressive activity of p14Arf on menin-
gioma transformation is p53-independent. Overall, our data
strongly support the view that one role of loss of p16Ink4 in menin-
giomagenesis could be to sensitize arachnoid cells to Nf2 loss.
Similarly, it has been suggested that one role of Ink4a-Arf loss in
gliomagenesis could be to sensitize astrocytes to transformation
through dedifferentiation in response to the appropriate oncogenic
stimuli (26).
In order to facilitate the validation, comparative analysis with
human tumors and use for drug screening in preclinical trials of the
mouse models, we have used the WHO classiﬁcation of human
meningiomas as a reference (10). However, some important differ-
ences exist between the human and murine lesions. In humans the
distinction of meningothelial hyperplasia, implying normal arach-
noidcellsthatproliferateasareactiveprocess,frommeningiomais
difﬁcultandreliesmostlyonclinicopathologicalfeaturesincluding
absenceofgrossvisibility,absenceofduralinvasionandofclinical
symptoms, and history of local inciting factors such as trauma,
hemorrhage, chronic inﬂammatory inﬁltrate, or adjacent tumor, or
asystemicconditionsuchasoldageorchronicrenalfailure.Histo-
logically meningothelial hyperplasia is deﬁned by the presence of
nests of 10 or more cell layers thick (16). In our mouse model
although the lesions are small, they are not reactive, but neoplastic,
as they are never observed in control mice at the site of injection.
Therefore, in the mouse, we preferred the term early tumors or
meningeal proliferations instead of meningeal hyperplasia.
Another difference that was noted was the high incidence of en
plaque meningiomas in the mouse model. In humans, en plaque
meningiomas represent an unusual growth pattern, manifested as a
carpet-like smooth or nodular dural thickening, which does not
raise above the dura mater but often invades adjacent skull, and is
often associated with hyperostosis. En plaque meningiomas in
humans are most common in the skull base, but may grow as
diffuse, ﬂat plaques over the convexities or form a circumferential
mass around the spinal cord (14). The histological features of the
mouse en plaque meningiomas were similar to those seen in
humans, but were not associated with hyperostosis and had no site
predilection. The higher frequency of en plaque meningiomas in
our mouse model is likely caused by the multifocality of Nf2 inac-
tivation induced by diffusion in the subarachnoid space of the
highly concentrated adCre vector suspension.
All the tumors in our mouse models were WHO grade I type
lesions. Interestingly, two tumors in adCre;Nf2ﬂox2/ﬂox2;Ink4a*/*
Figure 5. Murine intraspinal meningiomas show common magnetic
resonance imaging (MRI) features of human spinal meningioma. This
subdural-injected adCre;Nf2
ﬂox2/ﬂox2;Ink4a*
/* 8-month-old mouse rapidly
developed paraparesis. A. Axial T1-weighted image showing a large,
histologically conﬁrmed, Gd-DTPA-enhanced ﬁbroblastic meningioma
(arrowhead) compressing the spinal cord (asterisk). B. Remarkably, a
tailing of the meningioma along the dura mater (arrowhead) was present
at a lower level. A dural tail is often noted associated with human
meningiomas and known as “dural tail sign”. C. Sagittal view of spinal
cord (asterisk) showing the spinal meningioma (arrowhead).
Preclinical Mouse Model of Meningioma Kalamarides et al
68 Brain Pathology 18 (2008) 62–70
© 2007 The Authors; Journal Compilation © 2007 International Society of Neuropathologymice showed atypical features (prominent nucleoli, crowded cells).
In humans these atypical features may imply a more aggressive
clinical course. In the mouse, we have no clinical data to support or
refute the signiﬁcance of an atypical histological feature in a men-
ingioma, but as this was a model in which synergic action of Nf2
and p16Ink4a inactivation was assumed, it is of interest to note the
presence of histological features that may connote a more aggres-
sivetumor.Analysisofalargerseriesoftumorswouldbeneededto
determine the relevance of this observation and may lead to the
formulation of a modiﬁed WHO classiﬁcation for mouse models,
similar to the one formulated for peripheral nerve sheath tumors in
mouse models (25).
Here we show also that, as in humans, MRI can be used to image
meningiomas in the mouse. By using MRI to screen a large cohort
of mice rather than a few “interesting” mice, we were able to
determine the time-course of meningothelial proliferation and
meningioma development. For screening, we imaged mice using a
gradient echo sequence with short acquisition-time sequences
(only 6 minutes). With this relatively short scan time, we could
achievesufﬁcientsignal–noiseratioandimagespatialresolutionto
detect most meningiomas and meningothelial proliferations. To
increase the sensitivity of meningioma detection by MRI, it would
benecessarytoincreaseimageresolution,butatwofoldincreaseof
image resolution would result in an increase of scan time by four
fold. Therefore, the balance between reasonable data acquisition
timeandadequatespatialresolutionhastobeconsidered.Acrucial
step in the translation of this mouse meningioma model into a
preclinical model was the ability to detect meningothelial prolif-
eration by MRI. Follow-up of these early meningiomas with a
non-invasive imaging technique provides an additional readout in
preclinical studies for chemoprevention of NF2-related tumors.
Finally, monitoring meningioma growth by MRI opens the way
to future studies in which therapeutic intervention on sporadic
meningioma can be tested in this mouse model as preclinical
assessments of the potential for clinical application.
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